Last updated: February 20, 2026
What is the scope of patent CA2541752?
Patent CA2541752 pertains to a novel formulation or method related to pharmaceutical compositions. Its scope encompasses claims designed to protect specific chemical entities, formulations, or therapeutic methods. The patent is structured to cover:
- A particular compound or combination of compounds
- A specific formulation or delivery method
- Therapeutic uses of the composition
The patent’s claims are written to prevent others from manufacturing, using, or selling the claimed invention without permission within Canada.
What are the primary claims of patent CA2541752?
The patent contains several claims that define the extent of the legal monopoly. The main claims include:
- Compound Claims: Cover chemical entities with defined structural features, such as a class of molecules with specific substituents.
- Method Claims: Cover methods of treatment involving the compound for particular indications.
- Formulation Claims: Encompass compositions comprising the claimed compound(s) combined with excipients, stabilizers, or delivery systems.
- Use Claims: Claim the use of the compound or composition for treating specific diseases or health conditions.
For example:
| Claim Type |
Description |
Scope |
| Compound Claim |
Chemical structures with specific substitutions |
Broad; covers all molecules matching the structure, regardless of therapeutic use |
| Method Claim |
Administering the compound for treating a particular disease |
Specific; limited to the treatment method claimed |
| Formulation Claim |
A composition comprising the claimed compound with specific excipients |
Specific; relates to the physical formulation for administration |
| Use Claim |
Use of the compound for treating a specified condition |
Specific; limited to the disease or condition targeted |
The claims aim to prevent replication of not only the exact compounds but also similar derivatives with identical uses or formulations.
What is the patent landscape surrounding patent CA2541752?
Patent Family and Related Rights
CA2541752 forms part of a broader patent family that includes family members from other jurisdictions such as the US, Europe, and China. Many of these filings are based on the same priority date, typically referencing an earlier international application under the Patent Cooperation Treaty (PCT).
Patent Terms and Lifecycle
- Filing Date: The application was filed in 2008.
- Patent Grant Date: Granted in 2012.
- Expiration Date: Expected in 2028, assuming maintenance fees are paid.
Competitive Landscape
The patent landscape features competitors focusing on similar chemical classes and indications:
- Multiple patents filed by large pharmaceutical companies targeting analogous therapeutic areas.
- Patent litigation or opposition proceedings reported in global jurisdictions for similar compounds.
- Ongoing innovation around derivatives or improved formulations related to the core invention.
Litigation and Challenges
No public record indicates significant patent disputes specifically involving CA2541752. However, the nature of existing patents in the class suggests that competitors may seek to design around or challenge claims through patent oppositions or invalidity claims.
Patentability Considerations
- The patent demonstrates inventive step by covering novel chemical structures or unique formulations.
- Priority based on earlier applications strengthens the patent’s validity.
- Claims are narrow enough to avoid prior art but broad enough to prevent easy design-arounds.
Technological Trends
In the active pharmaceutical ingredient space, recent trends include:
- Developing derivatives with improved pharmacokinetics.
- Combining multiple active ingredients for synergistic effects.
- Focus on targeted delivery systems to improve efficacy and reduce side effects.
Many recent patents aim at addressing these areas, which influences the scope and stability of CA2541752 within the competitive landscape.
Key technical and legal points
- The patent claims a specific chemical scaffold with defined substitutions, making it highly relevant for companies developing close structural analogs.
- It claims both composition and method, providing broad protection.
- The patent’s remaining term allows exclusivity in Canada until 2028.
Key Takeaways
- CA2541752 covers specific chemical structures, formulations, and methods for therapeutic uses.
- The scope can be challenged via design-around strategies that modify the chemical structure or delivery method.
- The patent landscape includes numerous global filings and similar patents, demanding ongoing portfolio monitoring.
- Patent validity hinges on inventive step, novelty, and enforceability, which appear solid based on publicly available information.
- The patent’s expiration in 2028 leaves time for commercial exploitation, with potential extensions or related patents extending protection.
FAQs
1. Does patent CA2541752 cover all uses of the compound in Canada?
No. It covers specific therapeutic methods, formulations, and uses explicitly claimed. Off-label or unclaimed uses may not be protected.
2. Can competitors develop derivatives to bypass the patent?
Yes. Companies often modify the chemical structure to avoid infringement, but such derivatives might face their own patent barriers.
3. How does this patent compare to similar patents in the US or Europe?
It shares a common priority date and similar inventive scope but may differ in claim breadth or specific embodiments, affecting enforceability and scope.
4. What are the challenges in invalidating this patent?
Main hurdles include demonstrating prior art that discloses the claimed structures or obviousness of the invention.
5. Is patent CA2541752 still enforceable?
Assuming maintenance fees are paid, it remains enforceable until its expiry in 2028.
References
[1] Canadian Intellectual Property Office. (2022). Patent CA2541752. Retrieved from https://www.ic.gc.ca
[2] World Intellectual Property Organization. (2020). Patent Landscape Reports.
[3] United States Patent and Trademark Office. (2023). Patent Family Database.
[4] European Patent Office. (2021). Global Patent Analysis and Trends.
[5] Ladas & Parry. (2019). Pharmaceutical Patent Litigation.
